Showing results (191-200 of 203) with videos related to
Sort By:
Pageof 21
Proceedings of the National Academy of Sciences of the United States of America|May 30, 2023
17β-estradiol promotes extracellular vesicle release and selective miRNA loading in ERα-positive breast cancerRares Drula, Barbara Pardini, Xiao Fu, et al.Breast Cancer Research : BCR|May 7, 2026
The ARTEMIS trial identifies immune activation as a key predictor of neoadjuvant chemotherapy response in triple-negative breast cancerSahil Seth, Clinton Yam, Lei Huo, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 4, 2012
Specific lymphocyte subsets predict response to adoptive cell therapy using expanded autologous tumor-infiltrating lymphocytes in metastatic melanoma patientsLaszlo G Radvanyi, Chantale Bernatchez, Minying Zhang, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 29, 2020
Cumulative Incidence and Predictors of CNS Metastasis for Patients With American Joint Committee on Cancer 8th Edition Stage III MelanomaLauren E Haydu, Serigne N Lo, Jennifer L McQuade, et al.The Lancet. Oncology|January 24, 2018
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trialRodabe N Amaria, Peter A Prieto, Michael T Tetzlaff, et al.Nature|October 26, 2022
Neoadjuvant relatlimab and nivolumab in resectable melanomaRodabe N Amaria, Michael Postow, Elizabeth M Burton, et al.Nature Medicine|October 10, 2018
Neoadjuvant immune checkpoint blockade in high-risk resectable melanomaRodabe N Amaria, Sangeetha M Reddy, Hussein A Tawbi, et al.Nature Medicine|October 27, 2018
Author Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanomaRodabe N Amaria, Sangeetha M Reddy, Hussein A Tawbi, et al.Nature Medicine|October 27, 2018
Publisher Correction: Neoadjuvant immune checkpoint blockade in high-risk resectable melanomaRodabe N Amaria, Sangeetha M Reddy, Hussein A Tawbi, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 1, 2018
Prospective Analysis of Adoptive TIL Therapy in Patients with Metastatic Melanoma: Response, Impact of Anti-CTLA4, and Biomarkers to Predict Clinical OutcomeMarie-Andrée Forget, Cara Haymaker, Kenneth R Hess, et al.Pageof 21